Want to see APRE full AI Analyst Report?
Top Page
Aprea Therapeutics
(NASDAQ:APRE)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.80
▼(-20.10% Downside)
Action:Reiterated
Date:06/18/26
The score is held down primarily by weak financial performance (ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events provide some offset via fresh financing and reported clinical progress, but negative earnings and no dividend limit valuation support.
Positive Factors
Low leverage / no debt
Aprea's virtually debt-free balance sheet materially reduces refinancing and interest-rate risk, giving management flexibility to fund clinical programs and prioritize R&D without near-term interest obligations. This structural strength improves survival odds during extended development timelines.
Negative Factors
Persistent cash burn
Operating and free cash flow remain consistently negative (TTM ~ -$12.2M), indicating ongoing burn despite improvement versus earlier periods. Continued cash outflow requires future funding rounds or partnerships, creating dilution and execution risk over the medium term if trial costs rise or enrollment slows.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no debt
Aprea's virtually debt-free balance sheet materially reduces refinancing and interest-rate risk, giving management flexibility to fund clinical programs and prioritize R&D without near-term interest obligations. This structural strength improves survival odds during extended development timelines.
Read all positive factors
Aprea Therapeutics (APRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.19M
Dividend YieldN/A
Average Volume (3M)55.77K
Price to Earnings (P/E)―
Beta (1Y)2.10
Revenue Growth-90.40%
EPS Growth34.76%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.75
Shares Outstanding12,382,776
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-4.50
Enterprise Value/Revenue-350.53
Enterprise Value/Gross Profit23.01
Enterprise Value/Ebitda3.47
Forecast
1Y Price Target
$4.30Price Target Upside330.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$1.07M
Aprea Therapeutics Business Overview & Revenue Model
Company Description
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The comp...
How the Company Makes Money
null...
Aprea Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 118.11K | 0.00 | 1.50M | 583.23K | 0.00 | 0.00 |
| Gross Profit | -1.80M | 0.00 | -7.86M | 576.18K | -16.40M | -271.68K |
| EBITDA | -11.93M | -12.58M | -12.94M | -14.28M | -37.37M | -36.86M |
| Net Income | -11.95M | -12.60M | -12.96M | -14.29M | -112.66M | -36.54M |
Balance Sheet | ||||||
| Total Assets | 48.11M | 15.93M | 23.98M | 22.65M | 30.16M | 56.82M |
| Cash, Cash Equivalents and Short-Term Investments | 46.47M | 14.60M | 22.85M | 21.61M | 28.79M | 53.08M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 190.47K |
| Total Liabilities | 5.30M | 3.49M | 4.67M | 4.39M | 4.51M | 7.32M |
| Stockholders Equity | 42.82M | 12.44M | 19.31M | 18.26M | 25.64M | 49.51M |
Cash Flow | ||||||
| Free Cash Flow | -12.22M | -12.89M | -13.57M | -12.27M | -25.01M | -37.69M |
| Operating Cash Flow | -12.22M | -12.89M | -13.56M | -12.18M | -25.01M | -37.69M |
| Investing Cash Flow | 0.00 | 0.00 | -15.48K | -93.09K | 0.00 | 0.00 |
| Financing Cash Flow | 39.38M | 4.64M | 14.82M | 5.14M | 682.97K | 1.75M |
Aprea Therapeutics Technical Analysis
Negative
1.00
Price Trends
0.82
Negative
0.81
Negative
0.96
Negative
Market Momentum
-0.02
Positive
43.26
Neutral
27.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APRE, the sentiment is Negative. The current price of 1 is above the 20-day moving average (MA) of 0.76, above the 50-day MA of 0.82, and above the 200-day MA of 0.96, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.26 is Neutral, neither overbought nor oversold. The STOCH value of 27.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APRE.
Aprea Therapeutics Risk Analysis
Aprea Therapeutics disclosed 79 risk factors in its most recent earnings report. Aprea Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aprea Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $21.71M | -1.39 | -74.15% | ― | -24.96% | 46.11% | |
50 Neutral | $13.59M | -0.37 | -96.39% | ― | ― | 80.68% | |
45 Neutral | $9.19M | -0.42 | -87.05% | ― | -90.40% | 34.76% | |
44 Neutral | $5.49M | -0.13 | -253.43% | ― | ― | 97.61% | |
43 Neutral | $9.26M | -0.26 | -334.42% | ― | ― | 86.17% |
* Healthcare Sector Average
APRE
Aprea Therapeutics
0.73
-1.00
-57.92%
ERNA
Eterna Therapeutics
5.93
-42.82
-87.84%
QNRX
Quoin Pharmaceuticals
4.67
-4.22
-47.47%
NCNA
Nucana
1.24
-8.80
-87.65%
VYNE
VYNE Therapeutics
0.67
-0.75
-52.68%
INAB
IN8bio
1.40
-0.89
-38.86%
Aprea Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
Aprea Shareholders Approve Directors, Reverse Split Flexibility
Positive
Jun 17, 2026
At its annual meeting of stockholders held on June 16, 2026, Aprea Therapeutics, Inc. reported that a quorum of approximately 66.8% of eligible shares was present and stockholders elected three Class I directors, Marc Duey, Richard Peters and Bern...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
Positive
May 13, 2026
On May 13, 2026, Aprea Therapeutics reported first-quarter 2026 results and a corporate update, highlighting clinical progress for WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 trial, including two partial responses and generally favorable to...
Business Operations and StrategyPrivate Placements and Financing
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
Positive
Apr 1, 2026
Aprea Therapeutics, Inc., a clinical-stage precision oncology company developing targeted therapies for biomarker-defined cancers, has advanced a pipeline led by APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, for solid tumor in...
Business Operations and StrategyPrivate Placements and Financing
Aprea Therapeutics Announces $30 Million Private Placement
Positive
Mar 30, 2026
On March 30, 2026, Aprea Therapeutics entered into a securities purchase agreement for an oversubscribed private placement of pre-funded and common stock warrants to raise approximately $30 million in gross proceeds, with closing expected on or ab...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.